Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Tirzepatide: Evidence Summary
Evidence summary for Tirzepatide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Tirzepatide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Weight loss (obesity) | Tier A | 7 | SURMOUNT trials demonstrated 20-26% body weight reduction; superior to semaglutide in head-to-head |
| Type 2 diabetes | Tier A | 9 | SURPASS trials showed HbA1c reductions up to 2.46% — strongest glycemic data for any incretin therapy |
| Heart failure with preserved EF | Tier B | 1 | SUMMIT trial showed improvement in heart failure symptoms in obese patients |
| NASH/NAFLD | Tier B | 1 | Phase 2b showed significant NASH resolution without worsening fibrosis |
| Prediabetes prevention | Tier B | 1 | 94% risk reduction in progression from prediabetes to type 2 diabetes |
References (13)
- Tirzepatide for Obesity Treatment and Diabetes Prevention. . The New England journal of medicine (2025) PMID: 39536238
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. . The New England journal of medicine (2025) PMID: 40353578
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. . The New England journal of medicine (2025) PMID: 39555826
- Tirzepatide for overweight and obesity management. . Expert opinion on pharmacotherapy (2025) PMID: 39632534
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. . BMJ (Clinical research ed.) (2024) PMID: 38286487
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. . JAMA (2024) PMID: 38078870
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. . JAMA (2024) PMID: 38819983
- Tirzepatide: A Review in Type 2 Diabetes. . Drugs (2024) PMID: 38388874
- Medications for Obesity: A Review. . JAMA (2024) PMID: 39037780
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease. . American heart journal (2024) PMID: 37758044
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). . The New England journal of medicine (2022) PMID: 35658024
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). . The New England journal of medicine (2021) PMID: 34170647
- Tirzepatide versus Placebo in Type 2 Diabetes (SURPASS-1). . The New England journal of medicine (2021) PMID: 34186022